Novartis ends eight-year cancer drug dispute for $182m

Case dismissed with settlement between Novartis and Daiichi Sankyo unit | Melanoma therapy at centre of feud after Novartis faced infringement claims over Tafinlar.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Force pharma companies to provide drugs for rare cancer trials, UK govt told

30 January 2024 MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body.

Big Pharma

Novartis asks court for access to rival’s documents over trade secrets claims

26 October 2023 Swiss multinational says competitor has been “uncooperative” in investigation into whether former Novartis employee took trade secrets |Novartis files complaint for discovery, asking for permission to issue subpoena.

Big Pharma

Why Novartis lost its treatment dispute with Teva

17 January 2023 The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.

More features

US generics company wins patent battle over Merck Serono’s blockbuster MS drug

Novartis counsel warns: ‘Don’t let AI develop without our input’

Squires: ‘Inherited patent backlog was an absolute dumpster fire’

Delegates descend upon Washington, DC for AIPLA Annual Meeting

Novo Nordisk counters rival with $9bn bid for obesity drug developer

‘We're being attacked from all sides’: Thermo Fisher Scientific counsel

China trademarks rankings reveal new entries, hidden gems and big brands

Edwards defends key heart valve product from infringement threat

Novartis ends eight-year cancer drug dispute for $182m

More on this story

Editor's picks

Editor's picks

More features